摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-hydroxy-2,2-dimethyl-1-propanesulfonamide | 132115-56-1

中文名称
——
中文别名
——
英文名称
3-hydroxy-2,2-dimethyl-1-propanesulfonamide
英文别名
3-hydroxy-2,2-dimethylpropane-1-sulfonamide
3-hydroxy-2,2-dimethyl-1-propanesulfonamide化学式
CAS
132115-56-1
化学式
C5H13NO3S
mdl
——
分子量
167.229
InChiKey
LUIBHMKLKJNEQI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    327.3±44.0 °C(Predicted)
  • 密度:
    1.254±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.6
  • 重原子数:
    10
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    88.8
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    6-氯-2-甲基咪唑并[1,2-b]吡嗪3-hydroxy-2,2-dimethyl-1-propanesulfonamide 在 sodium hydride 作用下, 生成 2,2-Dimethyl-3-(2-methylimidazo[1,2-b]pyridazin-6-yl)oxypropane-1-sulfonamide
    参考文献:
    名称:
    缩合唑衍生物的合成研究。IV。ω-氨磺酰基烷基氧基咪唑并[1,2-b]哒嗪的合成及抗哮喘活性。
    摘要:
    合成了一系列新颖的(咪唑并[1,2-b]哒嗪-6-基)氧基烷基磺酰胺,并评估了其抑制血小板活化因子(PAF)诱导的豚鼠支气管收缩的能力。发现在侧链的氨磺酰基丙氧基的2位上带有宝石二烷基或亚环烷基的化合物具有有效的活性。其中,3-(咪唑并[1,2-b]哒嗪-6-基)氧基-2,2-二甲基丙烷磺酰胺(6)具有优良的抗哮喘活性,且作用时间最长。发现在咪唑并[1,2-b]哒嗪环的7或8位带有甲基的化合物具有增强的活性。其中,3-(7-甲基咪唑并[1,2-b]哒嗪-6-基)氧基-2,2-二甲基丙烷磺酰胺(25)表现出最强的抑制作用,在过敏性哮喘实验模型中的抗哮喘作用优于茶碱。讨论了这一系列化合物中的构效关系。
    DOI:
    10.1248/cpb.44.122
  • 作为产物:
    描述:
    3-hydroxy-2,2-dimethyl-1-propylthiocyanate 在 吡啶sodium methylate 作用下, 以 甲醇二氯甲烷 为溶剂, 反应 50.5h, 生成 3-hydroxy-2,2-dimethyl-1-propanesulfonamide
    参考文献:
    名称:
    缩合唑衍生物的合成研究。IV。ω-氨磺酰基烷基氧基咪唑并[1,2-b]哒嗪的合成及抗哮喘活性。
    摘要:
    合成了一系列新颖的(咪唑并[1,2-b]哒嗪-6-基)氧基烷基磺酰胺,并评估了其抑制血小板活化因子(PAF)诱导的豚鼠支气管收缩的能力。发现在侧链的氨磺酰基丙氧基的2位上带有宝石二烷基或亚环烷基的化合物具有有效的活性。其中,3-(咪唑并[1,2-b]哒嗪-6-基)氧基-2,2-二甲基丙烷磺酰胺(6)具有优良的抗哮喘活性,且作用时间最长。发现在咪唑并[1,2-b]哒嗪环的7或8位带有甲基的化合物具有增强的活性。其中,3-(7-甲基咪唑并[1,2-b]哒嗪-6-基)氧基-2,2-二甲基丙烷磺酰胺(25)表现出最强的抑制作用,在过敏性哮喘实验模型中的抗哮喘作用优于茶碱。讨论了这一系列化合物中的构效关系。
    DOI:
    10.1248/cpb.44.122
点击查看最新优质反应信息

文献信息

  • Triazolopyridazine compounds, their production and use
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US05389633A1
    公开(公告)日:1995-02-14
    Novel compound represented by the formula: ##STR1## wherein R.sup.1 stands for H, an optionally substituted lower alkyl group or a halogen; R.sup.2 and R.sup.3 respectively stands for a hydrogen or an optionally substituted lower alkyl group, or R.sup.2 and R.sup.3 may, taken together with the adjacent --C.dbd.C-- group, form a 5- to 7-membered ring; X stands for O, SO or SO.sub.2 ; Y stands for a group of the formula: ##STR2## (R.sup.4 and R.sup.5 respectively stand for H or an optionally substituted lower alkyl group) or a divalent group derived from an optionally substituted 3- to 7-membered homocyclic or heterocyclic ring; R.sup.6 and R.sup.7 each stands for H, an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group or an optionally substituted aryl group, or R.sup.6 and R.sup.7 may, taken together with the adjacent N, form an optionally substituted N-containing heterocyclic group; m stands for 0 to 4; n stands for 0 to 4, or a salt thereof, which has excellent anti-PAF activities anti-LTC.sub.4 activities and anti-ET-1 activities, and is of value as an antiasthmatic agent, and their production, intermediates and pharmasceutical compositions.
    由以下公式表示的新型化合物:##STR1## 其中 R.sup.1 代表 H,一个可选地取代的低级烷基团或一个卤素;R.sup.2 和 R.sup.3 分别代表一个氢或一个可选地取代的低级烷基团,或者 R.sup.2 和 R.sup.3 可以与相邻的 --C.dbd.C-- 基团一起形成一个 5 至 7 成员的环;X 代表 O, SO 或 SO.sub.2 ;Y 代表一个由以下公式表示的基团:##STR2## (R.sup.4 和 R.sup.5 分别代表 H 或一个可选地取代的低级烷基团)或一个由一个可选地取代的 3 至 7 成员的同环或杂环派生的二价基团;R.sup.6 和 R.sup.7 各自代表 H,一个可选地取代的低级烷基团,一个可选地取代的环烷基团或一个可选地取代的芳香基团,或者 R.sup.6 和 R.sup.7 可以与相邻的 N 一起形成一个可选地取代的含 N 杂环基团;m 代表 0 至 4;n 代表 0 至 4,或其盐,具有极好的抗-PAF 活性、抗-LTC.sub.4 活性和抗-ET-1 活性,作为抗哮喘剂具有价值,及其生产、中间体和药物组合物。
  • Synthetic Studies on Condensed-Azole Derivatives. III. Synthesis and Anti-asthmatic Activities of C-Substituted Alkyl Side Chain Derivatives of .OMEGA.-Sulfamoylalkylthioimidazo(1,2-b)pyridazines and Related Compounds.
    作者:Masaaki KUWAHARA、Yasuhiko KAWANO、Hiroshi SHIMAZU、Hiroaki YAMAMOTO、Yasuko ASHIDA、Akio MIYAKE
    DOI:10.1248/cpb.43.1516
    日期:——
    A series of novel alkylthioimidazo[1,2-b]pyridazines was synthesized and evaluated for ability to inhibit platelet activating factor (PAF)-induced bronchoconstriction in guinea pigs. Among them, 3-(imidazo[1,2-b]pyridazin-6-yl)thio-2,2-dimethylpropanesulfona mide (15) showed the most potent inhibitory effect. The structure-activity relationships in this series of compounds, in particular, the effects
    合成了一系列新颖的烷基硫代咪唑并[1,2-b]哒嗪,并评估了其抑制血小板活化因子(PAF)诱导的豚鼠支气管收缩的能力。其中,3-(咪唑并[1,2-b]哒嗪-6-基)硫代-2,2-二甲基丙烷磺酰胺(15)表现出最强的抑制作用。该系列化合物的结构活性关系,特别是咪唑并哒嗪环转化为其他杂环,在咪唑并哒嗪环的2或3位引入取代基以及将取代基引入环氧基的影响。还讨论了烷基侧链。
  • Synthetic Studies on Condensed-Azole Derivatives. V. Synthesis and Anti-asthmatic Activities of .OMEGA.-Sulfamoylalkyloxy(1,2,4)triazolo(1,5-b)pyridazines.
    作者:Masaaki KUWAHARA、Yasuhiko KAWANO、Masahiro KAJINO、Yasuko ASHIDA、Akio MIYAKE
    DOI:10.1248/cpb.45.1447
    日期:——
    A series of novel ([1, 2, 4]triazolo[1, 5-b]pyridazin-6-yl)oxyalkylsulfonamides was synthesized and evaluated for the ability to inhibit platelet activating factor (PAF)-induced bronchoconstriction in guinea pigs. The compounds bearing a gem-dialkyl or a cycloalkylidene group at the 2 position of the sulfamoylpropyloxy group in the side chain and a methyl group at the 7 position were found to have potent activity. Among them, 2, 2-diethyl-3-(7-methyl[1, 2, 4]-triazolo[1, 5-b]pyridazin-6-yl)oxypropanesulfonamide (13) showed excellent anti-asthmatic activity. Compounds 13 may be of significant value in the treatment of asthma and other respiratory diseases. The structure-activity relationships in this series of compounds are discussed.
    一系列新型[1, 2, 4]三唑并[1, 5-b]吡哒嗪-6-基氧烷基磺酰胺被合成并评估了其抑制血小板活化因子(PAF)诱导的豚鼠支气管收缩的能力。在侧链中,在磺酰氨基丙氧基的2位带有双烷基或环烷基亚基团以及在7位带有甲基的化合物显示出强效活性。其中,2, 2-二乙基-3-(7-甲基[1, 2, 4]三唑并[1, 5-b]吡哒嗪-6-基)氧丙烷磺酰胺(13)表现出优异的抗哮喘活性。化合物13可能在治疗哮喘和其他呼吸系统疾病方面具有重要价值。讨论了该系列化合物的构效关系。
  • Imidazopyridazines, their production and use
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US05491145A1
    公开(公告)日:1996-02-13
    Novel compound of the general formula: ##STR1## wherein R.sup.1 stands for a hydrogen atom, an optionally substituted lower alkyl group or a halogen atom; R.sup.2 and R.sup.3 respectively stand for a hydrogen atom or an optionally substituted lower alkyl group, provided that either R.sup.2 or R.sup.3 is a hydrogen atom, the other being an optionally substituted lower alkyl group, or R.sup.2 and R.sup.3 may, taken together with the adjacent --C=C-- group, form a 5- to 7-membered ring; X stands for an oxygen atom or S(O).sub.p (p stands for an integer from 0 to 2; Y stands for a group of the formula: ##STR2## (R.sup.4 and R.sup.5 respectively stand for a hydrogen atom or an optionally substituted lower alkyl group) or a divalent group derived from an optionally substituted 3- to 7-membered homocyclic or heterocyclic ring; R.sup.6 and R.sup.7 each stands for a hydrogen atom, an optionally substituted lower lakyl group, an optionally substituted cycloalkyl group or an optionally substituted aryl group, or R.sup.6 and R.sup.7 may, taken together with the adjacent nitrogen atom, form an optionally substituted nitrogen-containing heterocyclic group; m stands for an integer from 0 to 4; and n stands for an integer from 0 to 4, or a salt thereof, which has excellent anti-PAF activities, and is of value as an antiasthmatic agent, and their production, intermediates and pharmaceutical compositions.
    通用公式的新化合物:其中R.sup.1代表氢原子、可选择取代的低烷基基团或卤原子;R.sup.2和R.sup.3分别代表氢原子或可选择取代的低烷基基团,但R.sup.2或R.sup.3中的一个是氢原子,另一个是可选择取代的低烷基基团,或R.sup.2和R.sup.3可以与相邻的--C=C--基团一起形成5-至7-成员环;X代表氧原子或S(O).sub.p(p为0至2的整数);Y代表以下式的基团:其中R.sup.4和R.sup.5分别代表氢原子或可选择取代的低烷基基团,或源自可选择取代的3-至7-成员同环或异环环的双价基团;R.sup.6和R.sup.7分别代表氢原子、可选择取代的低烷基基团、可选择取代的环烷基基团或可选择取代的芳基基团,或R.sup.6和R.sup.7可以与相邻的氮原子一起形成可选择取代的含氮杂环基团;m为0至4的整数;n为0至4的整数,或其盐,具有优异的抗PAF活性,是一种抗哮喘药物,以及其制备、中间体和药物组成。
  • Imidazopyridazines and use as antiasthmatic agents
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US05155108A1
    公开(公告)日:1992-10-13
    The imidazo[1,2-b]pyridazine compounds of the formula: ##STR1## wherein R.sub.1 is a hydrogen or halogen atom, or a lower alkyl group optionally having substituent(s), R.sub.2 an R.sub.3 are, independently, a hydrogen atom, a lower alkyl group optionally having substituent(s), a cycloalkyl group or a phenyl group optionally having substituent(s) or R.sub.2 and R.sub.3 together with the adjacent nitrogen atom to which they bond may form a heterocyclic ring optionally having substituent(s), X is an oxygen atom or S(O)n (n=0 to 2), Alk is a straight or branched chain alkylene group containing 1-10 carbon atoms and optionally having substituent(s), or their pharmaceutically acceptable salts which possess antiallergic, anti-inflammatory and anti-PAF activities, and their production and use.
    式中R.sub.1为氢原子或卤素原子,或具有取代基的较低烷基基团,R.sub.2和R.sub.3分别为氢原子、具有取代基的较低烷基基团、环烷基基团或苯基基团,或者R.sub.2和R.sub.3与它们结合的相邻氮原子一起可以形成具有取代基的杂环环,X为氧原子或S(O)n(n=0至2),Alk为含有1-10个碳原子并且可能具有取代基的直链或支链烷基基团,或它们的药学上可接受的盐,具有抗过敏、抗炎和抗PAF活性,以及它们的生产和使用。
查看更多